

Chr. Hansen is a global bioscience company that develops natural solutions for the food, nutritional, pharmaceutical and agricultural industries. We develop and produce cultures, enzymes, probiotics and HMOs for a variety of foods, beverages, dietary supplements, animal feed and crop protection.

### ● Chr. Hansen Holding A/S



Previous Close	Currency	52 Weeks %	Volume	Number of Shares	Market Cap (bil.)
451.20	DKK	-11.81	283,899	131,852,496	59.5

### Key figures, EUR million

Income Statement (Cont. Operations)	2021/22	2020/21	2019/20	2018/19	2017/18
Revenue	1,218.0	1,077.4	970.0	937.4	1,097.4
Gross profit	676.5	613.4	584.0	576.9	600.6
EBITDA before special items	432.9	399.3	400.6	372.3	384.0
EBIT before special items	325.8	298.1	326.9	314.7	320.2
EBIT	320.9	276.2	313.0	312.4	320.2
Net financial items	(20.0)	(22.5)	(13.5)	(16.1)	(24.1)
Profit from continuing operations	225.1	198.7	231.6	229.2	228.2
Profit from discontinued operations	-	646.5	13.4	21.0	-
Profit for the year	225.1	845.2	245.0	250.2	228.2

Cash Flow (Group)	2021/22	2020/21	2019/20	2018/19	2017/18
Cash flow from operating activities	308.8	310.8	364.6	298.6	302.4
Cash flow from investing activities	(152.4)	284.5	(807.5)	(81.6)	(107.0)
Free cash flow	156.4	595.3	(442.9)	217.0	195.4
Free cash flow before acquisitions and special items	-	183.9	244.5	229.1	195.9
Free cash flow before acquisitions and special items, cont. operations	172.1	196.4	224.9	220.2	-

Balance Sheet (Group)	2021/22	2020/21	2019/20	2018/19	2017/18
Total assets <sup>1)</sup>	3,316.8	3,114.2	2,853.6	2,057.8	1,861.1
Invested capital <sup>1)</sup>	2,934.7	2,793.1	2,487.6	1,745.3	1,631.5
Net working capital	228.6	190.1	166.2	171.8	189.1
Equity <sup>1)</sup>	1,823.9	1,626.1	893.0	797.2	771.6
Net interest-bearing debt <sup>1)</sup>	880.6	898.2	1,345.0	734.4	658.7

Key Ratios	2021/22	2020/21	2019/20	2018/19	2017/18
<b>Continuing Operations</b>					
Organic growth <sup>2)</sup> , %	9	7	6	8	9
Gross margin, %	55.5	56.9	60.2	61.5	54.7
EBITDA margin before special items, %	35.5	37.1	41.3	39.7	35.0
EBIT margin before special items, %	26.8	27.7	33.7	33.6	29.2
EBIT margin, %	26.3	25.6	32.3	33.3	29.2
ROIC excl. goodwill, %	24.0	24.8	33.6	39.2	38.0
ROIC, %	11.4	11.6	16.5	20.0	19.9
R&D, %	8.1	8.5	8.0	8.1	7.3
Capital expenditure, %	11.6	14.5	12.2	12.6	9.8
Earnings per share diluted, EUR	1.71	1.51	1.76	1.74	-
Average number of employees (FTEs)	3,693	3,398	2,932	2,768	3,151

Group					
Earnings per share diluted, EUR	1.71	6.41	1.86	1.90	1.73
Net debt to EBITDA before special items	2.0x	2.3x	3.1x	1.8x	1.7x

Following the classification of the Natural Colors business as discontinued operations in 2019/20, the business is presented separately on an aggregated level in the income statement, balance sheet and cash flow statement. In accordance with IFRS, the income statement and cash flow statement have both been restated in previous periods, while the balance sheet has not been restated in previous periods. The comparative figures for 2017/18 have not been restated and are not directly comparable.


■ Numbers are not restated and therefore not directly comparable

■ IFRS16 was implemented using the retrospective approach, and comparative figures for 2018/19 have not been restated.

<sup>1)</sup> The Natural Colors business was sold on March 31, 2021. In 2017/18, total assets and invested capital included assets and liabilities related to the Natural Colors business.

<sup>2)</sup> Organic growth: Increase in revenue adjusted for sales reduction, acquisitions and divestments, and measured in local currency.

Revenue - Regional split (Cont. Operations), 2021/22



Revenue - Divisional split (Cont. Operations), 2021/22

